DBDavid BackPhDSlidesetHIVRio de Janeiro HIV Clinical Forum 2018DDIs, INSTIs, TB and hepatitis | David Back, PhDView Slideset
RDRicardo DiazMDSlidesetHIVRio de Janeiro HIV Clinical Forum 2018Transmitted resistance to ARVs and its impact on initial therapy | Ricardo Diaz, MDView Slideset
CBCharles BoucherMD, PhDSlidesetHIVRio de Janeiro HIV Clinical Forum 2018Resistance to Integrase Inhibitors | Charles Boucher, MD, PhDView Slideset
DBDavid BackPhDSlidesetHIVRio de Janeiro HIV Clinical Forum 2018Future perspective for delivery of antiretroviral drugs | David Back, PhDView Slideset
PCPedro CahnMD, PhDSlidesetHIVRio de Janeiro HIV Clinical Forum 2018Simplified regimens: pros and cons | Pedro Cahn, MD, PhDView Slideset
CBCarlos BritesMD, PhDSlidesetHIVRio de Janeiro HIV Clinical Forum 2018Optimal use of INSTI’s in routine practice | Carlos Brites, MD, PhDView Slideset
TVTânia VergaraMD, PhDSlidesetHIVRio de Janeiro HIV Clinical Forum 2018Clinical case presentation | Tânia Vergara, MD, PhDView Slideset
MSMauro SchechterMD, PhDSlidesetHIVRio de Janeiro HIV Clinical Forum 2018SIERJ SESSION: Is early ART for everyone? | Mauro Schechter, MD, PhDView Slideset
SlidesetHIVRio de Janeiro HIV Clinical Forum 2018Clinical case presentation | Marcio de Figueiredo Fernandes, MDView Slideset
VideoHIVMexican HIV Clinical Forum 2018Integrase Inhibitors in Women and Pediatrics | Alberto Chaparro-Sánchez, MDView Video
VideoHIVMexican HIV Clinical Forum 2018Optimal use of Integrase Inhibitors in Routine Patient Care in Mexico | Luis Soto-Ramirez, MDView Video
VideoHIVMexican HIV Clinical Forum 2018Clinical case presentation | Santiago Pérez Patrigeon, PhDView Video